1. Home
  2. HKIT vs TXMD Comparison

HKIT vs TXMD Comparison

Compare HKIT & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

N/A

Current Price

$1.07

Market Cap

25.2M

Sector

Technology

ML Signal

N/A

Logo TherapeuticsMD Inc.

TXMD

TherapeuticsMD Inc.

N/A

Current Price

$2.32

Market Cap

25.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HKIT
TXMD
Founded
1996
2008
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
25.9M
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
HKIT
TXMD
Price
$1.07
$2.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
67.4K
27.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
80.61
EPS
N/A
N/A
Revenue
N/A
$1,761,000.00
Revenue This Year
N/A
$427.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$90.64
Revenue Growth
N/A
35.25
52 Week Low
$0.53
$0.72
52 Week High
$4.21
$2.95

Technical Indicators

Market Signals
Indicator
HKIT
TXMD
Relative Strength Index (RSI) 28.57 52.54
Support Level N/A $1.05
Resistance Level $1.44 $2.54
Average True Range (ATR) 0.16 0.12
MACD -0.10 -0.01
Stochastic Oscillator 35.27 75.86

Price Performance

Historical Comparison
HKIT
TXMD

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Share on Social Networks: